Compare TWIN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | CHRS |
|---|---|---|
| Founded | 1918 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 296.8M |
| IPO Year | 1994 | 2014 |
| Metric | TWIN | CHRS |
|---|---|---|
| Price | $18.62 | $1.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 51.5K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $340,738,000.00 | N/A |
| Revenue This Year | $10.79 | $73.08 |
| Revenue Next Year | $8.43 | $30.94 |
| P/E Ratio | $10.40 | ★ N/A |
| Revenue Growth | ★ 15.45 | N/A |
| 52 Week Low | $6.90 | $0.72 |
| 52 Week High | $19.67 | $2.62 |
| Indicator | TWIN | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 55.16 | 42.56 |
| Support Level | $14.38 | $1.55 |
| Resistance Level | $18.83 | $1.80 |
| Average True Range (ATR) | 1.25 | 0.11 |
| MACD | 0.11 | -0.02 |
| Stochastic Oscillator | 68.59 | 6.93 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.